Profile data is unavailable for this security.
About the company
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
- Revenue in USD (TTM)0.00
- Net income in USD-14.33m
- Incorporated2000
- Employees25.00
- LocationImunon Inc997 Lenox Dr Ste 100LAWRENCEVILLE 08648United StatesUSA
- Phone+1 (609) 896-9100
- Fax+1 (609) 896-2200
- Websitehttps://imunon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioatla Inc | 0.00 | -64.71m | 8.86m | 61.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.5313 | 0.00 | -- | -- | 0.00 | -165.61 | -49.22 | -317.99 | -57.35 | -- | -- | -- | -3,690.17 | -- | -- | -- | -- | -- | 16.17 | 43.48 | -- | -- | -- |
| Pulmatrix Inc | 3.00k | -6.22m | 8.89m | 2.00 | -- | 1.88 | -- | 2,964.44 | -1.70 | -1.70 | 0.0008 | 1.30 | 0.0004 | -- | -- | 1,500.00 | -75.43 | -42.08 | -79.47 | -49.93 | -- | -- | -207,333.30 | -210.36 | -- | -- | 0.00 | -- | 6.96 | -0.2644 | 32.31 | -- | 46.99 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -10.09m | 9.29m | 16.00 | -- | 0.8276 | -- | -- | -5.87 | -5.87 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -60.63 | -- | -72.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Ernexa Therapeutics Inc | 1.00k | -18.36m | 9.32m | 6.00 | -- | 0.7104 | -- | 9,319.69 | -5.32 | -5.32 | 0.0002 | 0.4548 | 0.0001 | -- | 0.0059 | 166.67 | -264.07 | -187.10 | -2,044.59 | -237.72 | 100.00 | -- | -1,834,000.00 | -3,375.91 | -- | -2.73 | 0.00 | -- | 755.88 | -50.61 | -105.47 | -- | -19.54 | -- |
| Calcimedica Inc | 0.00 | -23.06m | 9.43m | 14.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0188 | 0.00 | -- | -- | 0.00 | -148.18 | -58.12 | -194.91 | -64.99 | -- | -- | -- | -- | -- | -- | 1.03 | -- | -- | -- | 60.12 | -- | -57.90 | -- |
| Bolt Biotherapeutics Inc | 5.20m | -42.68m | 9.50m | 52.00 | -- | 0.296 | -- | 1.83 | -22.27 | -22.27 | 2.71 | 16.72 | 0.0596 | -- | -- | 99,903.84 | -48.95 | -46.54 | -58.33 | -52.20 | -- | -- | -821.58 | -1,666.52 | -- | -- | 0.00 | -- | -2.36 | 104.50 | 8.79 | -- | -39.55 | -- |
| BioVie Inc | 0.00 | -17.48m | 9.58m | 13.00 | -- | 0.4971 | -- | -- | -5.13 | -5.13 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -72.35 | -260.69 | -79.73 | -454.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.73 | -- | -- | -- |
| Biomx Inc | 0.00 | -37.38m | 9.77m | 52.00 | -- | -- | -- | -- | -30.62 | -30.62 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -86.77 | -48.34 | -103.85 | -57.24 | -- | -- | -- | -- | -- | -57.02 | 0.00 | -- | -- | -- | 32.26 | -- | -53.03 | -- |
| Inotiv Inc | 514.03m | -69.37m | 9.80m | 1.95k | -- | 0.0899 | -- | 0.0191 | -2.02 | -2.02 | 15.00 | 3.17 | 0.6821 | 10.37 | 7.71 | 264,281.20 | -9.21 | -18.23 | -16.14 | -23.64 | 23.49 | 26.43 | -13.50 | -27.50 | 0.2218 | -0.6298 | 0.7918 | -- | 4.54 | 53.36 | 36.72 | -- | 21.79 | -- |
| LianBio - ADR | 0.00 | -87.98m | 9.83m | 163.00 | -- | 0.0482 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Imunon Inc | 0.00 | -14.33m | 9.98m | 25.00 | -- | 2.65 | -- | -- | -10.20 | -10.20 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -122.58 | -57.72 | -208.59 | -70.83 | -- | -- | -- | -7,752.42 | -- | -- | 0.00 | -- | -- | -- | 4.58 | -- | -38.98 | -- |
| Liminatus Pharma Inc | 0.00 | -2.27m | 10.18m | -- | -- | -- | -- | -- | -0.0872 | -0.0872 | 0.00 | -0.0608 | 0.00 | -- | -- | -- | -77.46 | -- | -- | -- | -- | -- | -- | -- | -- | -12.30 | -- | -- | -- | -- | 28.85 | -- | -- | -- |
| Ainos Inc | 113.04k | -14.96m | 10.61m | 44.00 | -- | 0.7254 | -- | 93.89 | -4.29 | -4.29 | 0.0307 | 2.10 | 0.0042 | 0.12 | 3,768.00 | 2,569.09 | -55.34 | -38.46 | -60.63 | -55.22 | 82.62 | 35.93 | -13,231.35 | -1,122.70 | 2.67 | -19.92 | 0.5227 | -- | -83.02 | 12.06 | -7.93 | -- | 10.22 | -- |
| Soligenix Inc | 0.00 | -11.46m | 10.99m | 14.00 | -- | 1.41 | -- | -- | -3.66 | -3.66 | 0.00 | 0.7705 | 0.00 | -- | -- | 0.00 | -105.25 | -73.79 | -165.82 | -151.46 | -- | 22.19 | -- | -1,147.93 | -- | -- | 0.00 | -- | -85.78 | -51.89 | -34.62 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -56.98m | 11.14m | 36.00 | -- | 10.29 | -- | -- | -1.22 | -1.22 | 0.00 | 0.0194 | 0.00 | -- | -- | 0.00 | -48.20 | -42.95 | -55.60 | -46.33 | -- | -- | -- | -- | -- | -- | 0.943 | -- | -- | -- | -81.07 | -- | 36.12 | -- |
Data as of Feb 13 2026. Currency figures normalised to Imunon Inc's reporting currency: US Dollar USD
6.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DRW Securities LLCas of 31 Dec 2025 | 58.83k | 2.33% |
| Riverview Capital Advisers LLCas of 30 Sep 2025 | 34.36k | 1.36% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 23.78k | 0.94% |
| Geode Capital Management LLCas of 31 Dec 2025 | 21.22k | 0.84% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 13.27k | 0.53% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.46k | 0.18% |
| Wells Fargo Clearing Services LLCas of 31 Dec 2025 | 3.44k | 0.14% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 2.96k | 0.12% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 1.39k | 0.06% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 1.03k | 0.04% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
